2011
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.
Petrylak D, Kantoff P, Rotshteyn Y, Israel R, Olson W, Ramakrishna T, Morris S. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer. Journal Of Clinical Oncology 2011, 29: 158-158. DOI: 10.1200/jco.2011.29.7_suppl.158.Peer-Reviewed Original ResearchMonomethyl auristatin EFree MMAEProstate cancer cellsProstate cancerRefractory metastatic prostate cancerDose-proportional PKTaxane-containing regimenCommon laboratory abnormalitiesDose-proportional mannerPhase I trialCancer cellsClinical disease progressionMetastatic prostate cancerOngoing phase IEnzyme-linked immunosorbent assay (ELISA) methodPotential clinical utilityImmunosorbent assay (ELISA) methodECOG statusAdverse eventsEscalation studyLaboratory abnormalitiesI trialThird dosesAntibody therapyLiquid chromatography/mass spectrometry/mass spectrometry method
1995
Preclinical studies of gossypol in prostate carcinoma.
Naik H, Petrylak D, Yagoda A, Lehr J, Akhtar A, Pienta K. Preclinical studies of gossypol in prostate carcinoma. International Journal Of Oncology 1995, 6: 209-13. PMID: 21556526, DOI: 10.3892/ijo.6.1.209.Peer-Reviewed Original ResearchProstate cancerHuman prostate adenocarcinoma cell line PC-3Hormone-refractory metastatic prostate cancerRefractory metastatic prostate cancerHormone-refractory prostate cancerRefractory prostate cancerMetastatic prostate cancerCell line PC-3MAT-LyLu cellsAnti-spermatogenic effectsPreclinical studiesProstate carcinomaNew agentsCopenhagen ratsDU-145Tumor growthIncurable diseaseMAT-LyLuHigh cytotoxic activityPC-3CancerCytotoxic activityGossypolActive agentsCarcinoma